SOURCE: OctoPlus N.V.

April 12, 2010 02:14 ET

OctoPlus publishes Annual Report 2009

LEIDEN, THE NETHERLANDS--(Marketwire - April 12, 2010) -

OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) announces today the publication of its Annual Report 2009 and other information related to the upcoming Annual General Meeting of Shareholders, which will take place on 12 May 2010.

During 2009, OctoPlus has made the transition into a drug delivery company. The Company is building a portfolio of compounds in development for clients, utilising its proprietary controlled release technologies. Key events during 2009 were:

§ Locteron successfully progressing through Phase IIb studies: top-line results to be presented this week at the EASL International Liver Congress

§ Growing adoption of OctoPlus' controlled release technology by the biotech and pharmaceutical industries through the acquisition of multiple technology evaluation projects

§ Increasing demand for formulation development and contract manufacturing services from existing and new customers

§ Successful completion of reorganisation to align organisational structure with new strategy

These events have resulted in record revenues of EUR 19 million, with highest ever core business (non-Locteron) revenues, and a positive EBITDA for the full year 2009.

The Annual Report is available on the Company's website, Hard copies of the report can be requested by sending an e-mail to

Annual General Meeting of Shareholders: 12 May in Leiden

The Annual General Meeting of Shareholders (AGM) will take place at the Company's headquarters in Leiden on 12 May 2010 at 14:00 Central European Time (CET). The agenda and other information regarding the AGM are available in the Investor Relations section on the Company's website.

For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524
1071, or
send an e-mail to Investor Relations at

About OctoPlus

OctoPlus is a drug delivery service company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward- looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.


Click here for the press release in PDF:

Contact Information